Epigallocatechin.

Gut and tissue esterases remove the gallate group from EGCG, producing epigallocatechin, so the two occupy the same metabolic chain. They also compete for the same COMT methylation and efflux routes.

Standardised green tea extract supplies epigallocatechin together with EGCG, epicatechin and caffeine. Isolated epigallocatechin shifts the ratio within a catechin pool the extract already delivers.

Epicatechin and epigallocatechin differ in the number of hydroxyl groups on the B ring and are conjugated by the same UGT, SULT and COMT enzymes. Co-ingestion slows conjugation of each and raises circulating free catechin.

Catechins oxidise quickly at intestinal pH, and ascorbate keeps the pyrogallol B ring reduced so more survives to be absorbed. Beverage and capsule formulas pair the two for exactly this reason.

The catechol and pyrogallol hydroxyls bind ferric iron into an insoluble complex in the gut lumen, so non-heme iron in the same meal is absorbed much less. Separating tea catechins from an iron dose by a couple of hours avoids the clash.

Ferrous sulfate dissociates to free iron in the stomach, which is exactly the form catechins precipitate. Taking the two together lowers iron uptake and can also darken the preparation as the iron-polyphenol complex forms.

Piperine inhibits intestinal UGT and P-glycoprotein, the two routes that clear catechins fastest on first pass. Less conjugation and less efflux mean more intact catechin reaching plasma, shown mainly in animal work so far.

Quercetin competes with catechins for catechol-O-methyltransferase and for the efflux pumps that push them back into the gut lumen. The reported result is a longer catechin presence in circulation, mostly from cell and animal models.

Caffeine blocks adenosine receptors and raises cyclic AMP, while catechins slow catechol-O-methyltransferase breakdown of noradrenaline. The two act at different points of the same normal thermogenic signal.

Catechins bind calcium and other divalent cations in the gut lumen through their phenolic hydroxyls, forming complexes that are less available for uptake. The effect is smaller than with iron but measurable at high catechin doses.

Green tea leaf delivers catechins and theanine in the same infusion, so the pairing reflects how the plant material is actually consumed rather than a designed combination. Theanine acts on neurotransmitter handling while the catechin fraction acts on redox chemistry, so the two do not compete for the same route. Human work on the pairing tends to test whole tea or whole extract, which means an effect cannot be assigned to one of the two.

Epigallocatechin and its gallate ester can be oxidised to reactive quinone species, and those species are handled by conjugation with glutathione before excretion. That places the catechin's own disposal partly inside the glutathione system rather than only in glucuronidation and methylation. The relationship runs both ways, since heavy catechin loads consume conjugating capacity.

The three adjacent hydroxyl groups on the B-ring bind divalent transition metals, copper included, forming complexes that are less available for absorption. This is the same chemistry that makes the molecule a hydrogen donor, so it cannot be separated from its antioxidant behaviour. Spacing a copper-containing product away from a concentrated catechin dose is the practical consequence.

Catechins bind divalent cations in the intestinal lumen, and zinc is one of the minerals affected in laboratory solubility work. The interaction happens before absorption, not inside the body, so hours of separation between doses removes it. The size of the effect on human zinc status has not been settled.

Cell-free and cell-culture work shows the gallate ester binding dihydrofolate reductase, the enzyme that reduces folate to its usable tetrahydro form. That is an in vitro observation about an enzyme, not a measured change in human folate status. Anyone taking a concentrated catechin extract alongside folate has reason to keep folate intake steady rather than assume the two are independent.

Most ingested catechin reaches the colon intact and is broken down by resident bacteria into smaller phenolic metabolites, so the microbial community determines what the body actually sees. A 2026 lamb study reports the microbiota as the mediating step for an intestinal effect of epigallocatechin, which is animal evidence for the mechanism rather than human evidence for an outcome. The pairing rationale is that the converting population is itself modifiable.

Inulin is fermented in the colon and changes which bacterial groups dominate there. Since colonic bacteria are what convert unabsorbed catechins into absorbable phenolic acids and valerolactones, changing the population plausibly changes the metabolite profile. This is a mechanistic expectation, not a measured pairing outcome in people.

Alpha-tocopherol stops lipid chain reactions in membranes and becomes a tocopheroxyl radical in the process, and water-soluble phenols can donate a hydrogen to return it to its active form. Catechins do this in laboratory lipid systems. Whether the recycling happens at achievable human tissue concentrations is not established.

EPA and DHA oxidise readily, and phenolic antioxidants delay that oxidation in oil systems. Catechins are used in this protective role in food and oil chemistry. The claim here is about the oil's stability, not about a clinical effect in the person taking it.

Silymarin flavonolignans and catechins are both handled by UGT and sulfotransferase enzymes and both inhibit some of those isoforms in vitro. Co-dosing could therefore alter the clearance of either one. No human pharmacokinetic study of the pairing is available to size that.